Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus, Inc. provides model-informed and AI-accelerated drug development software, training, and consulting services for biopharmaceutical research. News about the company centers on its software and services segments, scientific modeling engines, ADMET and other modeling workflows, and financial results tied to software renewals, services bookings, and customer activity.
Recurring developments also include collaborations with pharmaceutical companies, technology providers, and regulatory or public-health agencies. These updates cover GPU-accelerated simulation, AI-assisted modeling, predictive frameworks for complex oral drug products, computational toxicology, new approach methodologies, and education programs that expand use of model-informed drug development practices.
Simulations Plus (NASDAQ: SLP) has launched a new University+ Program offering free access to its modeling and simulation software for one year to students and educators at accredited universities worldwide. This initiative celebrates the company's 25th anniversary and aims to enhance education in Modeling and Simulation (M&S). Eligibility for renewal is available under certain conditions. The program seeks to prepare future scientists for careers in drug development and related fields, fostering academic research and collaboration.
Simulations Plus, Inc. has declared a quarterly cash dividend of $0.06 per share on its common stock. This dividend will be paid on November 1, 2021, to shareholders recorded as of October 25, 2021. Future dividends will be assessed quarterly based on earnings, financial condition, and capital requirements. Simulations Plus has been a leader in modeling and simulation software for drug discovery and development for 25 years, serving various industries globally.
Simulations Plus, Inc. (NASDAQ: SLP) will report its fourth quarter and full year financial results for fiscal year 2021, concluding on August 31, 2021, after market close on October 25, 2021. A conference call will follow at 5:00 PM ET that day, allowing stakeholders to discuss financial outcomes and future strategies. The call can be accessed via registration or dial-in. This announcement signifies an important upcoming milestone for the company in detailing its financial performance and operational updates.
Simulations Plus has received a cooperative agreement from the FDA, providing $250,000 annually for two years to enhance its GastroPlus® platform. This funding aims to improve the Transdermal Compartmental Absorption and Transit (TCAT™) model for better simulations of dermal formulations. The project will involve collaboration with leading pharmaceutical and research organizations, focusing on developing innovative strategies for regulatory assessments. This initiative strengthens the company's position in drug modeling and simulation, particularly in dermatology.
Simulations Plus, Inc. (Nasdaq: SLP) announced the release of version 10.3 of its ADMET Predictor platform, now marketed as APX.3. This update introduces enhanced AI capabilities, including a new AI-driven Drug Design Module that integrates third-party calculations for compound optimization. Key improvements include an updated CYP metabolism model and the MedChem Studio™ accessibility for all users, designed to bolster data visualization and analysis. The features aim to expand the client base and maintain double-digit revenue growth as the company enters its 2022 fiscal year.
Simulations Plus, Inc. (Nasdaq: SLP) announced that CEO Shawn O’Connor will present at the BofA Securities 2021 Tech Solutions for Drug Discovery Conference on September 20, 2021, at 10:00 a.m. ET, and at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 22, 2021, at 9:55 a.m. ET. One-on-one meetings will also be held at both events. Live webcasts and presentations will be accessible via the Investors page of the Simulations Plus website for 90 days.
Simulations Plus (Nasdaq: SLP) announced promising results from the second phase of a collaborative research project with a major pharmaceutical company. Nearly 30% of the 19 synthesized molecules demonstrated activity below 50 nM, indicating strong therapeutic potential. The predictive errors in rat and human microsomal clearance were improved by three-fold, showcasing advancements in the Artificial Intelligence-driven Drug Design (AIDD) Module of ADMET Predictor. The company plans to present further details in the coming months, along with functional updates to be released this fall.
Simulations Plus, Inc. (Nasdaq: SLP) has received a significant order from China's National Medical Products Administration (NMPA) to add licenses for its GastroPlus® software. This development underscores the growing adoption of physiologically based biopharmaceutics modeling in drug development. Division president John DiBella highlighted the expanding relationships with the NMPA and the positive impact on over 20 domestic Chinese pharmaceutical companies. The initiative aims to enhance regulatory review processes, potentially reducing time to market for new medicines, benefiting both companies and patients.
Simulations Plus, Inc. (Nasdaq: SLP) reported its third quarter fiscal 2021 results with total revenue of $12.8 million, up 4% year-over-year. Software revenue surged 21% to $8.3 million, while services revenue dropped 18% to $4.5 million. Gross profit rose 7% to $10.3 million, and net income increased 29% to $3.8 million. For the year-to-date, total revenue grew 14% to $36.6 million, bolstered by a 32% rise in software revenue. Despite project delays in services, the company anticipates full-year revenue growth of 5-10%.
Summary not available.